meRfi®-GM
Belantamab mafodotin & Multiple Myeloma (MM) / Plasmocytoma
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
The first antibody–drug conjugate in Multiple Myeloma (MM) / Plasmocytoma, belantamab mafodotin, was approved in August 2020 as a monotherapy for patients with relapsed or refractory myeloma who have received at least four prior lines of therapy.
…
References (Sources)
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- Belantamab mafodotin in the treatment of relapsed or refractory multiple myeloma
- Current developments in the combination therapy of relapsed/refractory multiple myeloma
- EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma